Case Report

Diagnosis and Treatment of Acute Pleural Effusion following Radioiodine Remnant Ablation Post Lobectomy for Thyroid Cancer

Xian Qiu 1,†, Pengwen Wang 2,†, Ri Sa 1,3, Lin Cheng 1, Yuchen Jin 1, Hongjun Song 1 and Libo Chen 1,*

1 Department of Nuclear Medicine, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Road, Shanghai 200233, China
2 Department of Thyroid Surgery, Panshi Hospital, 1 Kangfu Road, Panshi 132300, China
3 Department of Nuclear Medicine, The First Hospital of Jilin University, 71 Xinmin St., Changchun 130021, China
* Correspondence: lbchen@sjtu.edu.cn; Tel.: +86-21-24058871; Fax: +86-21-64941720
† These authors contributed equally to this work.

Abstract: Radioiodine remnant ablation (RRA) was previously demonstrated to be a safe and effective alternative to completion thyroidectomy for patients with differentiated thyroid cancer (DTC). However, its side effects have not been fully investigated, particularly in patients with lobectomy. We reported a young euthyroidal female who underwent RRA post lobectomy and lymph node dissection for papillary thyroid cancer, whose post-ablation 131I-whole-body scan accidentally showed diffuse radioiodine distribution on chest-mimicking pulmonary metastases. Immediately-added single-photon emission computed tomography/computed tomography (SPECT/CT), nevertheless, revealed a 131I-accumulating swollen left thyroid lobe and emerging pleural effusion, which relieved after short-term treatment with prednisone. In summary, acute pleural effusion ascribed to RRA-induced thoracic duct compression was reported for the first time. 131I-lobectomy-induced pleural effusion could be precisely diagnosed by SPECT/CT and efficiently manipulated via treating radiation thyroiditis with the short-term administration of corticosteroid.

Keywords: differentiated thyroid cancer; radioiodine remnant ablation; 131I-lobectomy; pleural effusion; thoracic duct

1. Introduction

Thyroid cancer is among the most common malignancies, with a steadily and rapidly increasing global incidence. In 2020, there were approximately 586,000 new cases worldwide, ranking it in 9th place [1]. Differentiated thyroid cancer (DTC), including papillary thyroid cancer, follicular thyroid cancer, and oncocytic thyroid cancer, accounts for >90% of all thyroid cancers [2,3]. Lung represents the most commonly involved organ by metastases from DTC, followed by bone [4], whereas metastasis to pleural is much less common, occupying nearly 0.6% [5–8].

Thyroidectomy followed by 131I therapy and L-thyroxine therapy represents the mainstay procedure to manage DTC. Recently, owing to the optimistic prognosis of patients with DTC and the popularization of the latest American Thyroid Association (ATA) guidelines, lobectomy has been suggested as an initial surgical procedure in DTC patients with lower risk of persistent/recurrent or metastatic disease [9,10]. Although lobectomy could largely avoid surgery-related complications, completion thyroidectomy may still be needed in clinical settings of patients with multicentric disease, unexpected extrathyroidal extension, lymph node involvement, etc. [11].

Radioiodine remnant ablation (RRA), a form of oral 131I therapy, represents a conventional treatment modality for patients with DTC. Via eradicating the thyroid remnant,
RRA is of great value to simplify response classification and facilitate dynamic risk stratification [12–14]. Moreover, accompanied post-ablation 131I whole-body scan (WBS) in combination with single-photon emission computed tomography/computed tomography (SPECT/CT) is of incremental value in disease surveillance and plays a vital role in the management of persistent/recurrent or metastatic disease [15]. At present, RRA has become a major part of therapeutic 131I administration, which also contains radioiodine adjuvant treatment for occult disease and radioiodine oncolytic treatment for known disease.

Recently, the ablation of the remaining whole-thyroid lobe by 131I, i.e., 131I-lobectomy, has been demonstrated to be a non-invasive, safe, and effective alternative to completion thyroidectomy for patients with DTC, which is especially favorable for those who are suffering from recurrent laryngeal nerve injury or parathyroid gland damage due to prior surgery [11,16]. However, the side effects of the 131I-lobectomy have not been sufficiently investigated, except for neck swelling and salivary disturbances [17–19].

Herein, we reported a case of 131I-lobectomy-induced acute pleural effusion mimicking lung metastatic DTC in a young female. Diagnostic procedures, treatment outcomes, and scientific hypothesis were described in detail.

2. Case Description

A 29-year-old female, who had undergone lobectomy plus therapeutic lymph node dissection for a 1.2-cm papillary thyroid cancer nodule with multiple nodal metastases, was referred to our institution for RRA, when she orally took L-thyroxine at a dose of 62.5 milligram (mg) per day, with a body weight of 55 kilogram (kg). After four weeks of L-thyroxine withdrawal before RRA, plain computed tomography scan showed no abnormal findings in the chest (no evidence of pleural disease), and the remaining left thyroid lobe (Figure 1A) measured 13 millimeter (mm) × 12 mm × 41 mm with normal blood flow by ultrasonography. All laboratory workup showed normal blood cell count, hepatic function, and thyroid function, with a thyroid-stimulating hormone (TSH) level of 2.86 mIU/L, a free triiodothyronine (FT3) level of 3.92 pmol/L, and a free thyroxine (FT4) level of 15.70 pmol/L (Figure 2).

An activity of 5.55 GBq (150 mCi) of 131I was then orally administered for lobe ablation. Simultaneously, prednisone at a dose of 20 mg three times daily was initiated and sustained for a week. On day three post 131I administration, WBS showed 131I distribution in the neck and chest (Figure 3). To precisely localize the 131I accumulation sites and reveal the underlying mechanism, SPECT/CT imaging was immediately added, showing a severely swollen left thyroid lobe (Figure 1B) and bilateral pleural effusion without solid metastatic lesions (Figure 3). Although the patient felt mild chest tightness at that time, respiratory symptoms and signs were not observed. Laboratory examinations indicated a leukocyte count of $10.8 \times 10^9/L$ with an increase in the proportion of neutrophils, a TSH level of 0.59 mIU/L, an FT3 level of 5.80 pmol/L, and an FT4 level of 26.80 pmol/L (Figure 2).

![Figure 1](image_url) Neck CT images showing the remaining left thyroid lobe before 131I administration (A), and 3 days (B) and 9 days (C) post 131I administration.
A 29-year-old female, who had undergone lobectomy plus therapeutic lymph node dissection for a 1.2-cm papillary thyroid cancer nodule with multiple nodal metastases, was referred to our institution for RRA, when she orally took L-thyroxine at a dose of 62.5 milligram (mg) per day, with a body weight of 55 kilogram (kg). After four weeks of L-thyroxine withdrawal before RRA, plain computed tomography scan showed no abnormal findings in the chest (no evidence of pleural disease), and the remaining left thyroid lobe (Figure 2A) measured 13 millimeter (mm) × 41 mm with normal blood flow by ultrasonography. All laboratory workup showed normal blood cell count, hepatic function, and thyroid function, with a thyroid-stimulating hormone (TSH) level of 2.86 mIU/L, a free triiodothyronine (FT3) level of 3.92 pmol/L, and a free thyroxine (FT4) level of 15.70 pmol/L.

Figure 1. Neck CT images showing the remaining left thyroid lobe before 131I administration (Figure 3). Whole-body scan (WBS) showing 131I distribution in the neck and chest (Figure 3). To precisely localize the 131I accumulation sites and reveal the underlying mechanism, SPECT/CT imaging was immediately added, showing a 131I-induced thyroiditis relieved robustly with a resetting trachea (Figure 1C). Moreover, the TSH level appeared, a follow-up WBS and SPECT/CT revealed no 131I accumulation in the chest, and the pleural effusion was absorbed completely (Figure 4). CT showed that the 131I-induced thyroiditis relieved robustly with a resetting trachea (Figure 1C). Moreover, the TSH level was started two weeks after 131I administration, yielding a favorable TSH level of 0.21 mIU/L, an FT3 level of 4.51 pmol/L, and an FT4 level of 26.60 pmol/L, after L-thyroxine replacement for one month.

Figure 2. Dynamic changes in serum parameters from day 0 to day 294 after 131I administration. FT3, free triiodothyronine (normal range: 3.67–6.00 pmol/L); FT4, free thyroxine (normal range: 7.50–21.10 pmol/L); TSH, thyroid-stimulating hormone (normal range: 0.34–5.60 mIU/L); Tg, thyroglobulin (normal range: 3.50–77.00 ng/mL); and TgAb, anti-Tg antibody (normal range: 0.00–115.00 IU/mL).

Figure 3. Whole-body scan ((A), anterior view; (B), posterior view) on day 3 post 131I administration, showing 131I distribution in left thyroid lobe and chest. SPECT/CT images of chest ((C–E), transaxial; (F–H), sagittal; and (I–K), coronal) showing bilateral pleural effusion, predominantly in the left side. Neither abnormal uptake nor lesion was found in either lung.

A diagnostic aspiration was refused by the patient, due to her experiencing no other discomfort. On day nine after 131I administration, when her chest tightness had disappeared, a follow-up WBS and SPECT/CT revealed no 131I accumulation in the chest, and the pleural effusion was absorbed completely (Figure 4). CT showed that the 131I-induced thyroiditis relieved robustly with a resetting trachea (Figure 1C). Moreover, the TSH level
of 0.47 mIU/L, the FT₃ level of 3.86 pmol/L, the FT₄ level of 19.10 pmol/L, the blood cell count, and the serum albumin level were all within normal ranges (Table 1). L-thyroxine replacement therapy at a dose of nearly 2 mg/kg of body weight was started two weeks after ¹³¹I administration, yielding a favorable TSH level of 0.21 mIU/L, an FT₃ level of 4.51 pmol/L, and an FT₄ level of 26.60 pmol/L, after L-thyroxine replacement for one month.

Table 1. Laboratory data before and after ¹³¹I administration.

|                        | Before ¹³¹I Administration | Day 9 after ¹³¹I Administration | Day 16 after ¹³¹I Administration |
|------------------------|---------------------------|----------------------------------|-----------------------------------|
| Leukocyte (×10⁹/L)    | 4.2                       | 4.9                              | 5.3                               |
| Neutrophil (×10⁹/L)   | 2.4                       | 4.1                              | 4.0                               |
| Albumin (g/L)         | 55                        | 46.5                             | 50.0                              |
| ALT (U/L)             | 18                        | 14                               | 12                                |
| AST (U/L)             | 20                        | 15                               | 16                                |
| TBIL (umol/L)         | 12.7                      | 8.2                              | 7.4                               |
| DBIL (umol/L)         | 2.5                       | 2.0                              | 1.8                               |
| Creatinine (umol/L)   | 54                        | 49.5                             | 55.4                              |
| eGFR-EPI (mL/min/1.73 m) | 122.89                   | 126.46                           | 121.86                            |
| proBNP (ng/mL)        | NA                        | 34.21                            | NA                                |

Leukocyte, (normal range: 3.5–9.5 × 10⁹/L); neutrophil, (normal range: 1.8–6.3 × 10⁹/L); albumin, (normal range: 35–55 g/L); ALT, alanine transaminase (normal range: 0–65 U/L); AST, aspartate aminotransferase (normal range: 8–37 U/L); TBIL, total bilirubin (normal range: 0.0–18.0 umol/L); DBIL, direct bilirubin (normal range: 0.0–6.0 umol/L); creatinine (normal range: 53–115 umol/L); and proBNP, pro B type natriuretic peptide (normal range: 5.0–125.00 ng/mL). NA, not available.

Ten months after the ¹³¹I-lobectomy, the successful RRA was verified and the excellent response was achieved in this patient, based on the outcomes of serum test and ultrasonography examination [14,18]. Specifically, the TSH level of 0.02 mIU/L, the thyroglobulin (Tg) level of 0.12 ng/mL, and the anti-Tg antibody (TgAb) level of 168.00 IU/mL were documented on
day 294 days post RRA (Figure 2). Moreover, ultrasonography showed that the left thyroid gland gradually shrank to 15 mm × 18 mm × 35 mm, 13 mm × 17 mm × 25 mm, and 9 mm × 12 mm × 25 mm at one, four, and ten months post RRA, respectively. Meanwhile, neither blood flow in the ablated thyroid lobe nor nodal disease in the neck was found during the above ultrasound examinations.

3. Discussion

An increase in thyroid lobectomy for patients with DTC has become a trend in the latest decade, especially after the 2015 ATA guidelines were issued [9,11]. Consequently, more challenges in RRA may be met during real-word nuclear medicine practice in treating DTC patients who have undergone thyroid lobectomy. Our patient was classified as intermediate risk, mainly based on her postoperative pathological findings, and $^{131}$I therapy should be considered, according to the 2015 ATA guidelines [10]. Compared with completion thyroidectomy, which might carry complications for patients, a non-invasive and safe RRA may be chosen by patients [11] because RRA is critical to facilitate response classification post initial treatment and dynamic recurrence risk stratification by Tg measurement and WBS. Consistent with other studies [14,20–22], the successful RRA and excellent therapeutic response allowed our patient a decrease in the frequency of follow-up and the degree of TSH suppression because a recurrence risk of only 1–4% and a disease-specific death of merely < 1% could be expected [10]. Moreover, for the first time, acute pleural effusion was reported as a new side effect of RRA, which was precisely diagnosed by SPECT/CT fusion imaging and efficiently treated by the short-term use of corticosteroid.

As is well known, DTC metastases were the most common pathologically malignant etiologies of $^{131}$I uptake in the chest views of planar imaging, including spot view and WBS. Owing to the improvement of diagnostic accuracy by incorporating hybrid SPECT/CT in the last two decades, most causes of $^{131}$I uptake in rare clinical settings could be identified, with incremental value in the management of patients with DTC, as previously described by our group [23,24]. Recently, extremely scarce cases of solitary breast metastasis from DTC and transplantation in endoscopic thyroidectomy were reported [25,26]. Furthermore, $^{131}$I-avid malignancies beyond DTC have been identified by $^{131}$I WBS with or without SPECT/CT, such as primary lung cancer, gastric adenocarcinoma, metastatic salivary gland tumor, and papillary meningioma [27].

Pathologically benign etiologies in the chest have also been recognized to accumulate $^{131}$I, including bronchiectasis, respiratory bronchiolitis, pulmonary tuberculosis, pulmonary aspergilloma, breast fibroadenoma, pleuropneumonic cyst, hyperplastic thymus, bronchial atresia with mucocele, and pulmonary sequestration [27–29]. Potential mechanisms of $^{131}$I uptake in these entities were deemed as increased concentration of $^{131}$I due to the hyperemia of the inflamed mucosa, the leakage of $^{131}$I into bronchial tree or lung parenchyma because of increased permeability, and the accumulation of tracheobronchial secretions due to decreased clearance [30]. In contrast to DTC lesions, which commonly show persistent $^{131}$I uptake, chronic pulmonary inflammation usually manifest transient $^{131}$I uptake, which may be revealed by repeated WBS. More importantly, significant information simultaneously provided by the diagnostic CT compartment of SPECT/CT plays a vital role in the differential diagnoses.

Additionally, $^{131}$I distribution viewed in the chest has even been found in physiological conditions. Firstly, esophageal retention could be misdiagnosed, when a planar image illustrates focal or diffuse uptake rather than linear uptake. The underlying mechanisms involve the retention of saliva due to decreased esophageal motility, mechanical obstruction, or pooling of saliva in the posterior pharyngeal pouch, secondary to achalasia, esophageal stricture, and Zenker’s diverticulum [31–33]. Although delayed planar images may be helpful for the final diagnosis, since the retention of $^{131}$I in the esophagus changes or disappears with time, an immediately added SPECT/CT may help reveal the cause readily, which is similarly applied to identify physiological $^{131}$I uptake by gastric and colonic mucosa of aberrant locations in the chest [34]. Secondly, lactating breast can take up
Acute side effects of RRA should not be ignored since they often bring patients divergent discomforts. Gastrointestinal discomforts represent the most common 131I therapy-related symptoms, in which nausea and levels could be associated with lower recurrence rate compared to those with an increased TgAb level during excellent response to the initial management. It was reported by other studies that patients with decreased TgAb however, the declining Tg level accompanied by the decreasing TgAb level indicated a favorable outcome, i.e., an follow-up.

Based on the dynamic data on serum parameters we continuously obtained (Figure 5), the FT4 level dropped promptly after a transient enhancement on day nine, and L-thyroxine replacement therapy was started at two weeks after 131I administration, yielding favorable values of TSH, FT3, and FT4. Thus, we deem that two weeks replacement therapy after 131I administration remains unclear in DTC patients post lobectomy, due to the lack of DTC who had undergone total or near-total thyroidectomy. However, the optimal timing to start L-thyroxine replacement therapy after 131I administration represents an appropriate timing to start L-thyroxine replacement therapy in this entity.

Notably, according to the ultrasound features of our patient during 10 months of follow-up after RRA, the remaining thyroid gland continuously shrank with the absence of blood flow, indicating a mummified thyroid lobe. Furthermore, the value of TgAb decreased gradually after a transient increase post the RRA (Figure 2). It has been highlighted that TgAb should be detected together with Tg, similar to the mode of change in the anti-TSH antibody level.

Figure 5. Surgical anatomy of neck illustrating carotid sheath (arrow) and thoracic duct (arrow head) of another patient, showing that thoracic duct passes posterior to the left common carotid artery and injects into the left venous angle.
Traditionally, L-thyroxine replacement therapy was usually started 48 h after 131I administration in patients with DTC who had undergone total or near-total thyroidectomy. However, the optimal timing to start L-thyroxine replacement therapy after 131I administration remains unclear in DTC patients post lobectomy, due to the lack of pertinent data. Based on the dynamic data on serum parameters we continuously obtained (Figure 2), the FT4 level dropped promptly after a transient enhancement on day nine, and L-thyroxine replacement therapy was started at two weeks after 131I administration, yielding favorable values of TSH, FT3, and FT4. Thus, we deem that two weeks after 131I administration represents an appropriate timing to start L-thyroxine replacement therapy in this entity.

Notably, according to the ultrasound features of our patient during 10 months of follow-up after RRA, the remaining thyroid gland continuously shrank with the absence of blood flow, indicating a mummified thyroid lobe in line with the findings previously reported by our team [14]. Furthermore, the value of TgAb decreased gradually after a transient increase post the RRA (Figure 2), similar to the mode of change in the anti-TSH antibody level post RRA in patients with Graves’ disease [46]. It has been highlighted that TgAb should be detected together with Tg during the follow-up of patients with DTC due to its potential interference with Tg assay [47]. To date, nevertheless, the cut-off value of TgAb has not been established, to avoid interference [48,49]. In our patient, however, the declining Tg level accompanied by the decreasing TgAb level indicated a favorable outcome, i.e., an excellent response to the initial management. It was reported by other studies that patients with decreased TgAb levels could be associated with lower recurrence rate compared to those with an increased TgAb level during follow-up [50,51].

Acute side effects of RRA should not be ignored since they often bring patients divergent discomforts. Gastrointestinal discomforts represent the most common 131I therapy-related symptoms, in which nausea and vomiting usually occur within 36 hours after 131I administration. Salivary gland swelling, pain, and dysfunction, which may develop into dry mouth after patients are discharged from the hospital, have attracted continuous attention since there is no effective precaution approach [52]. Additionally, neck pain and swelling due to thyroiditis have been reported in up to 50–66% patients with lobectomy undergoing RRA, and such symptoms usually resolve after oral administration of paracetamol or corticosteroid for a few days [11]. It was reported that 8.3–26.5% of subjects who experienced moderate or severe symptoms recovered after taking prednisone 20–40 mg/day for 3 days, subsequently tapered over 7–10 days [20,53]. Instead of initiating prednisone when patients developed significant neck pain and swelling, nevertheless, our patients were prophylactically given corticosteroid in a short course. Moreover, the dose of 60 mg daily in our case was higher than those reported in the previous studies [20]. All of the modulations above might be attributable to the more efficient control of 131I-induced thyroiditis in the intact lobe. As expected, our patient did not suffer from neck pain and dyspnea, except for neck swelling and mild chest tightness. Notably, expect for the transient and mild increase in leukocyte count, there were no other adverse events caused by the short-term use of corticosteroid, indicating an excellent safety profile of this medication regimen [54].

4. Conclusions

Our case report indicated that the 131I-lobectomy represents an acceptable alternative to completion thyroidectomy in patients with DTC. We firstly identified acute pleural effusion attributable to RRA-induced thoracic duct compression, which could be precisely diagnosed by SPECT/CT and efficiently manipulated by treating radiation thyroiditis with the short-term use of corticosteroid.

Author Contributions: X.Q., H.S. and P.W. collected data; X.Q. analyzed the data and drafted the manuscript; R.S., L.C. (Lin Cheng) and Y.J. revised the manuscript; and L.C. (Libo Chen) designed the study and revised the paper; all authors contributed to data interpretation. All authors have read and agreed to the published version of the manuscript.
Funding: This study was sponsored by the National Natural Science Foundation of China Grant (No. 82171981).

Institutional Review Board Statement: All of the methods performed in our study involving human participants were approved using the ethical standards of the Ethics Committee of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital (approval code: 2000-022).

Informed Consent Statement: Written informed consent was obtained from the participant enrolled in the study.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

DTC, differentiated thyroid cancer; ATA, American Thyroid Association; RRA, radioiodine remnant ablation; WBS, whole-body scan; SPECT/CT, single-photon emission computed tomography/computed tomography; TSH, thyroid-stimulating hormone; FT3, free triiodothyronine; FT4, free thyroxine; Tg, thyroglobulin; and TgAb, anti-Tg antibody.

References

1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [CrossRef] [PubMed]
2. Haugen, B.R.; Alexander, E.K.; Bible, K.C.; Doherty, G.M.; Mandel, S.J.; Nikiforov, Y.E.; Pacini, F.; Randolph, G.W.; Sawka, A.M.; Schlumberger, M.; et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016, 26, 1–133. [CrossRef] [PubMed]
3. Baloch, Z.W.; Asa, S.L.; Barletta, J.A.; Ghossein, R.A.; Juhlin, C.C.; Jung, C.K.; LiVolsi, V.A.; Papotti, M.; editors. Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocr. Pathol. 2022, 33, 27–63. [CrossRef] [PubMed]
4. Nixon, I.J.; Whitcher, M.M.; Palmer, F.L.; Tuttle, R.M.; Shaha, A.R.; Shah, J.P.; Patel, S.G.; Ganly, I. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid 2012, 22, 884–889. [CrossRef]
5. Tamura, T.; Shiozawa, T.; Sato, H.; Kagoshita, K.; Takayashiki, N.; Hizawa, N. Pleural fluid due to papillary thyroid cancer. Oncol. Lett. 2019, 18, 962–966. [CrossRef]
6. Olson, M.T.; Nuransoy, A.; Ali, S.Z. Malignant pleural effusion resulting from metastasis of thyroid primaries: A cytomorphological analysis. Acta Cytol. 2013, 57, 177–183. [CrossRef]
7. Hsu, K.F.; Hsieh, C.B.; Duh, Q.Y.; Chien, C.F.; Li, H.S.; Shih, M.L. Hürthle cell carcinoma of the thyroid with contralateral malignant pleural effusion. Onkologie 2009, 32, 47–49. [CrossRef]
8. Vassilopoulou-Sellin, R.; Sneige, N. Pleural effusion in patients with differentiated papillary thyroid cancer. South. Med. J. 1994, 87, 1111–1116. [CrossRef]
9. Zhu, C.Y.; Sha, S.; Tseng, C.H.; Yang, S.E.; Otto, L.E.; Levin, M.; Wong, C.W.; Livhits, M.J.; Rao, J.; Yeh, M.W. Trends in the Surgical Management of Known or Suspected Differentiated Thyroid Cancer at a Single Institution, 2010–2018. Thyroid 2020, 30, 1639–1645. [CrossRef]
10. Gulec, S.A.; Ahuja, S.; Avram, A.M.; Bernet, V.J.; Bourguet, P.; Draganescu, C.; Elisei, R.; Giovanella, L.; Grant, F.; Greenspan, B.; et al. A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer. Thyroid 2021, 31, 1009–1019. [CrossRef]
11. Piccardo, A.; Trimboli, P.; Bottini, G.; Giovanella, L. Radioiodine Ablation of Remaining Thyroid Lobe in Patients with Differentiated Thyroid Cancer Treated by Lobectomy: A Systematic Review and Metaanalysis. J. Nucl. Med. 2020, 61, 1730–1735. [CrossRef]
12. Cabanillas, M.E.; McFadden, D.G.; Durante, C. Thyroid cancer. Lancet 2016, 388, 2783–2795. [CrossRef]
13. Pryma, D.A.; Mandel, S.J. Radioiodine therapy for thyroid cancer in the era of risk stratification and alternative targeted therapies. J. Nucl. Med. 2014, 55, 1485–1491. [CrossRef]
14. Jin, Y.; Ruan, M.; Cheng, L.; Fu, H.; Liu, M.; Sheng, S.; Chen, L. Radioiodine Uptake and Thyroglobulin-Guided Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Prospective, Randomized, Open-Label, Controlled Trial. Thyroid 2019, 29, 101–110. [CrossRef]
15. Ahn, B.C.; Lee, S.W.; Lee, J.; Kim, C. Pulmonary aspergilloma mimicking metastasis from papillary thyroid cancer. Thyroid 2011, 21, 555–558. [CrossRef]
16. Tan, M.P.; Agarwal, G.; Reeve, T.S.; Barraclough, B.H.; Delbridge, L.W. Impact of timing on completion thyroidectomy for thyroid cancer. Br. J. Surg. 2002, 89, 802–804. [CrossRef]
17. Bal, C.S.; Kumar, A.; Chandra, P.; Dwivedi, S.N.; Pant, G.S. A prospective clinical trial to assess the efficacy of radioiodine ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer undergoing sub-total thyroidectomy. Acta Oncol. 2006, 45, 1067–1072. [CrossRef]
18. Schlumberger, M.; Catargi, B.; Borget, I.; Deandres, D.; Zerdoud, S.; Bridji, B.; Bardet, S.; Leenhardt, L.; Bastie, D.; Schwartz, C.; et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N. Engl. J. Med. 2012, 366, 1663–1673. [CrossRef]
19. Untch, B.R.; Palmer, F.L.; Ganly, I.; Patel, S.G.; Michael Tuttle, R.; Shah, J.P.; Shaha, A.A. Oncologic outcomes after completion thyroidectomy for patients with well-differentiated thyroid carcinoma. Ann. Surg. Oncol. 2014, 21, 1374–1378. [CrossRef]
20. Giovanella, L.; Piccardo, A.; Paone, G.; Poppiani, L.; Treglia, G.; Ceriani, L. Thyroid lobe ablation with iodine. 131 I in patients with differentiated thyroid carcinoma: A randomized comparison between 1.1 and 3.7 GBq activities. Nucl. Med. Commun. 2013, 34, 767–770. [CrossRef]
21. Hoyes, K.P.; Owens, S.E.; Millns, M.M.; Allan, E. Differentiated thyroid cancer: Radioiodine following lobectomy—A clinical feasibility study. Nucl. Med. Commun. 2004, 25, 245–251. [CrossRef] [PubMed]
22. Randolph, G.W.; Daniels, G.H. Radioactive iodine lobe ablation as an alternative to completion thyroidectomy for follicular carcinoma of the thyroid. Thyroid 2002, 12, 989–996. [CrossRef] [PubMed]
23. Tong, J.; Ruan, M.; Jin, Y.; Fu, H.; Cheng, L.; Luo, Q.; Liu, Z.; Lv, Z.; Chen, L. Poorly differentiated thyroid carcinoma: A clinician’s perspective. Eur. Thyroid J. 2021, 11, e220201. [CrossRef] [PubMed]
24. Chen, L.; Luo, Q.; Shen, Y.; Yu, Y.; Yuan, Z.; Lu, H.; Zhu, R. Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma. J. Nucl. Med. 2008, 49, 1952–1957. [CrossRef] [PubMed]
25. Wang, A.; Fu, W.; Deng, Y.; He, L.; Zhang, W. False-Positive 131I Uptake After Transareola Endoscopic Thyroidectomy in a Patient With Papillary Thyroid Carcinoma. Clin. Nucl. Med. 2022, 47, 324–325. [CrossRef]
26. Kharroubi, D.; Richa, C.; Saie, C.; Chami, L.; Lussey-Lepoutre, C. Solitary Breast Metastasis From Thyroid Papillary Carcinoma Revealed on Whole-Body Radioactive 131I Scan. Clin. Nucl. Med. 2020, 45, 687–688. [CrossRef]
27. Bakheet, S.M.; Powe, J.; Hammami, M.M. Radioiodine uptake in the chest. J. Nucl. Med. 1997, 38, 984–986.
28. Spinapinosa, E.G.; Chytiris, S.; Fuccio, C.; Leporati, P.; Volpato, G.; Villani, L.; Trifiro, G.; Chiovato, L. Pulmonary sequestration: A (131)I whole body scintigraphy false-positive result. Ann. Nucl. Med. 2014, 28, 683–687. [CrossRef]
29. Lee, W.H.; Park, J.M.; Kwak, J.J. A solitary large radioiodine accumulative lung lesion in high-dose 131i therapeutic scan: Bronchial atresia with mucocoele. Clin. Nucl. Med. 2015, 40, 149–152. [CrossRef]
30. Höschl, R.; Choy, D.H.; Gandevia, B. Iodine-131 uptake in inflammatory lung disease: A potential pitfall in treatment of thyroid carcinoma. J. Nucl. Med. 1988, 29, 701–706.
31. Bakheet, S.; Hammami, M.M. False-positive thyroid cancer metastasis on whole-body radioiodine scanning due to retained radioactivity in the oesophagus. J. Nucl. Med. 1991, 30, 198–202. [CrossRef] [PubMed]
32. Duong, R.B.; Fernandez-Ulloa, M.; Planitz, M.K.; Maxon, H.R. I-123 breast uptake in a young primipara with postpartum transient thyrotoxicosis. Clin. Nucl. Med. 1983, 8, 35. [CrossRef] [PubMed]
33. Lin, D.S. Thyroid imaging–mediastinal uptake in thyroid imaging. Clin. Nucl. Med. 1990, 15, 604–608. [CrossRef]
34. Bakheet, S.M.; Hammami, M.M. Patterns of radioiodine uptake by the lactating breast. Eur. J. Nucl. Med. 1994, 21, 604–608. [CrossRef] [PubMed]
35. Hammami, M.M.; Bakheet, S. Radioiodine breast uptake in nonbreastfeeding women: Clinical and scintigraphic characteristics. J. Nucl. Med. 1996, 37, 26–31.
36. Schneider, J.A.; Divgi, C.R.; Scott, A.M.; Macapinlac, H.A.; Sonenberg, M.; Goldsmith, S.J.; Larson, S.M. Hiatal hernia on whole-body radioiodine survey mimicking metastatic thyroid cancer. Clin. Nucl. Med. 1993, 18, 751–753. [CrossRef]
37. Bakheet, S.; Hammami, M.M. Spurious lung metastases on radioiodine thyroid and whole body imaging. Clin. Nucl. Med. 1993, 18, 307–312. [CrossRef]
38. Bakheet, S.M.; Hammami, M.M. Spurious thyroid cancer bone metastases on radioiodine scan due to external contamination. Eur. J. Radiol. 1993, 16, 239–242. [CrossRef]
39. Gritters, L.S.; Wissing, J.; Gross, M.D.; Shapiro, B. Extensive salivary contamination due to concurrent use of chewing tobacco during I-131 radioablative therapy. Clin. Nucl. Med. 1993, 18, 115–117. [CrossRef]
40. Peng, D.; Shao, F. Even Small Pleural Effusion Could Be Potential Pitfall on Posttherapeutic 131I Scintigraphy. Clin. Nucl. Med. 2020, 45, 925–926. [CrossRef]
41. Gottehrehr, A.; Roa, J.; Stanford, G.G.; Chernow, B.; Sahn, S.A. Hypothyroidism and pleural effusions. Chest 1990, 98, 1130–1132. [CrossRef]
42. Jany, B.; Welte, T. Pleural Effusion in Adults-Etiology, Diagnosis, and Treatment. Dtsch. Ärzteblatt Int. 2019, 116, 377–386. [CrossRef]
43. Light, R.W. Pleural effusions. Med. Clin. N. Am. 2011, 95, 1055–1070. [CrossRef]
44. Johnson, O.W.; Chick, J.F.; Chauhan, N.R.; Fairchild, A.H.; Fan, C.M.; Stecker, M.S.; Killoran, T.P.; Suzuki-Han, A. The thoracic duct: Clinical importance, anatomic variation, imaging, and embolization. Eur. Radiol. 2016, 26, 2482–2493. [CrossRef]
46. Laurberg, P.; Wallin, G.; Tallstedt, L.; Abraham-Nordling, M.; Lundell, G.; Tørring, O. TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: A 5-year prospective randomized study. Eur. J. Endocrinol. 2008, 158, 69–75. [CrossRef]

47. Rosario, P.W.; Cortes, M.C.S.; Franco Mourao, G. Follow-up of patients with thyroid cancer and antithyroglobulin antibodies: A review for clinicians. Endocr. Relat. Cancer 2021, 28, R111–R119. [CrossRef]

48. Spencer, C.; Fatemi, S. Thyroglobulin antibody (TgAb) methods—Strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer. Best Pract. Res. Clin. Endocrinol. Metab. 2013, 27, 701–712. [CrossRef]

49. Liu, Q.; Yin, M.; Li, G. Antithyroglobulin Antibody Variation During Follow-Up Has a Good Prognostic Value for Preoperative Antithyroglobulin Antibody-Positive Differentiated Thyroid Cancer Patients: A Retrospective Study in Southwest China. Front. Endocrinol. 2021, 12, 774275. [CrossRef]

50. Kim, W.G.; Yoon, J.H.; Kim, W.B.; Kim, T.Y.; Kim, E.Y.; Kim, J.M.; Ryu, J.S.; Gong, G.; Hong, S.J.; Shong, Y.K. Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 2008, 93, 4683–4689. [CrossRef]

51. Rosario, P.W.; Carvalho, M.; Mourão, G.F.; Calsolari, M.R. Comparison of Antithyroglobulin Antibody Concentrations Before and After Ablation with 131I as a Predictor of Structural Disease in Differentiated Thyroid Carcinoma Patients with Undetectable Basal Thyroglobulin and Negative Neck Ultrasonography. Thyroid 2016, 26, 525–531. [CrossRef] [PubMed]

52. Lu, L.; Shan, F.; Li, W.; Lu, H. Short-Term Side Effects after Radioiodine Treatment in Patients with Differentiated Thyroid Cancer. BioMed Res. Int. 2016, 2016, 4376720. [CrossRef] [PubMed]

53. Long, B.; Li, L.; Yao, L.; Chen, S.; Yi, H.; Ye, X.; Xu, D.; Wu, P. Combined use of radiiodine therapy and radiofrequency ablation in treating postsurgical thyroid remnant of differentiated thyroid carcinoma. J. Cancer Res. Ther. 2015, 11, C244–C247. [CrossRef] [PubMed]

54. Granger, J.M.; Kontoyiannis, D.P. Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: A retrospective, single-institution study. Cancer 2009, 115, 3919–3923. [CrossRef]